Abstract
Summary
The global Bruton Tyrosine Kinase (BTK) Inhibitor market size is projected to grow from US$ 866.7 million in 2022 to US$ 1834.6 million in 2029; it is expected to grow at a CAGR of 11.3% from 2023 to 2029.
United States market for Bruton Tyrosine Kinase (BTK) Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Bruton Tyrosine Kinase (BTK) Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Bruton Tyrosine Kinase (BTK) Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Bruton Tyrosine Kinase (BTK) Inhibitor players cover Pfizer, Aptose Eiosciences, BeiGene, Hanmi Phamaceutical, Eli Lilly, Merck, Ono Phamaceutical, AbbVie and Zhejiang DTRM Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development. Currently, BTK inhibitors are mainly applied in the treatments of hematological malignancies.
LPI (LP Information)' newest research report, the “Bruton Tyrosine Kinase (BTK) Inhibitor Industry Forecast” looks at past sales and reviews total world Bruton Tyrosine Kinase (BTK) Inhibitor sales in 2022, providing a comprehensive analysis by region and market sector of projected Bruton Tyrosine Kinase (BTK) Inhibitor sales for 2023 through 2029. With Bruton Tyrosine Kinase (BTK) Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bruton Tyrosine Kinase (BTK) Inhibitor industry.
This Insight Report provides a comprehensive analysis of the global Bruton Tyrosine Kinase (BTK) Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bruton Tyrosine Kinase (BTK) Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Bruton Tyrosine Kinase (BTK) Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bruton Tyrosine Kinase (BTK) Inhibitor and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bruton Tyrosine Kinase (BTK) Inhibitor.
This report presents a comprehensive overview, market shares, and growth opportunities of Bruton Tyrosine Kinase (BTK) Inhibitor market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Tablet
Capsule
Segmentation by application
Chronic Lymphocytic Leukemia (CLL)
Follicular Lymphoma
Mantle Cell Lymphoma
Waldenstrom Macroglobulinemia
Other Selective B Cell Malignancies
Chronic Graft-versus-host Disease
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Aptose Eiosciences
BeiGene
Hanmi Phamaceutical
Eli Lilly
Merck
Ono Phamaceutical
AbbVie
Zhejiang DTRM Biopharma
AstraZeneca
Biogen
Key Questions Addressed in this Report
What is the 10-year outlook for the global Bruton Tyrosine Kinase (BTK) Inhibitor market?
What factors are driving Bruton Tyrosine Kinase (BTK) Inhibitor market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Bruton Tyrosine Kinase (BTK) Inhibitor market opportunities vary by end market size?
How does Bruton Tyrosine Kinase (BTK) Inhibitor break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
United States market for Bruton Tyrosine Kinase (BTK) Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Bruton Tyrosine Kinase (BTK) Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Bruton Tyrosine Kinase (BTK) Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Bruton Tyrosine Kinase (BTK) Inhibitor players cover Pfizer, Aptose Eiosciences, BeiGene, Hanmi Phamaceutical, Eli Lilly, Merck, Ono Phamaceutical, AbbVie and Zhejiang DTRM Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development. Currently, BTK inhibitors are mainly applied in the treatments of hematological malignancies.
LPI (LP Information)' newest research report, the “Bruton Tyrosine Kinase (BTK) Inhibitor Industry Forecast” looks at past sales and reviews total world Bruton Tyrosine Kinase (BTK) Inhibitor sales in 2022, providing a comprehensive analysis by region and market sector of projected Bruton Tyrosine Kinase (BTK) Inhibitor sales for 2023 through 2029. With Bruton Tyrosine Kinase (BTK) Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bruton Tyrosine Kinase (BTK) Inhibitor industry.
This Insight Report provides a comprehensive analysis of the global Bruton Tyrosine Kinase (BTK) Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bruton Tyrosine Kinase (BTK) Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Bruton Tyrosine Kinase (BTK) Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bruton Tyrosine Kinase (BTK) Inhibitor and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bruton Tyrosine Kinase (BTK) Inhibitor.
This report presents a comprehensive overview, market shares, and growth opportunities of Bruton Tyrosine Kinase (BTK) Inhibitor market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Tablet
Capsule
Segmentation by application
Chronic Lymphocytic Leukemia (CLL)
Follicular Lymphoma
Mantle Cell Lymphoma
Waldenstrom Macroglobulinemia
Other Selective B Cell Malignancies
Chronic Graft-versus-host Disease
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Aptose Eiosciences
BeiGene
Hanmi Phamaceutical
Eli Lilly
Merck
Ono Phamaceutical
AbbVie
Zhejiang DTRM Biopharma
AstraZeneca
Biogen
Key Questions Addressed in this Report
What is the 10-year outlook for the global Bruton Tyrosine Kinase (BTK) Inhibitor market?
What factors are driving Bruton Tyrosine Kinase (BTK) Inhibitor market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Bruton Tyrosine Kinase (BTK) Inhibitor market opportunities vary by end market size?
How does Bruton Tyrosine Kinase (BTK) Inhibitor break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Bruton Tyrosine Kinase (BTK) Inhibitor by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Bruton Tyrosine Kinase (BTK) Inhibitor by Country/Region, 2018, 2022 & 2029
2.2 Bruton Tyrosine Kinase (BTK) Inhibitor Segment by Type
2.2.1 Tablet
2.2.2 Capsule
2.3 Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Type
2.3.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales Market Share by Type (2018-2023)
2.3.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue and Market Share by Type (2018-2023)
2.3.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sale Price by Type (2018-2023)
2.4 Bruton Tyrosine Kinase (BTK) Inhibitor Segment by Application
2.4.1 Chronic Lymphocytic Leukemia (CLL)
2.4.2 Follicular Lymphoma
2.4.3 Mantle Cell Lymphoma
2.4.4 Waldenstrom Macroglobulinemia
2.4.5 Other Selective B Cell Malignancies
2.4.6 Chronic Graft-versus-host Disease
2.4.7 Others
2.5 Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Application
2.5.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sale Market Share by Application (2018-2023)
2.5.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue and Market Share by Application (2018-2023)
2.5.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sale Price by Application (2018-2023)
3 Global Bruton Tyrosine Kinase (BTK) Inhibitor by Company
3.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Breakdown Data by Company
3.1.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Annual Sales by Company (2018-2023)
3.1.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales Market Share by Company (2018-2023)
3.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Annual Revenue by Company (2018-2023)
3.2.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Company (2018-2023)
3.2.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue Market Share by Company (2018-2023)
3.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sale Price by Company
3.4 Key Manufacturers Bruton Tyrosine Kinase (BTK) Inhibitor Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Bruton Tyrosine Kinase (BTK) Inhibitor Product Location Distribution
3.4.2 Players Bruton Tyrosine Kinase (BTK) Inhibitor Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Bruton Tyrosine Kinase (BTK) Inhibitor by Geographic Region
4.1 World Historic Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Geographic Region (2018-2023)
4.1.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Country/Region (2018-2023)
4.2.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Annual Sales by Country/Region (2018-2023)
4.2.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Annual Revenue by Country/Region (2018-2023)
4.3 Americas Bruton Tyrosine Kinase (BTK) Inhibitor Sales Growth
4.4 APAC Bruton Tyrosine Kinase (BTK) Inhibitor Sales Growth
4.5 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Sales Growth
4.6 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitor Sales Growth
5 Americas
5.1 Americas Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Country
5.1.1 Americas Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Country (2018-2023)
5.1.2 Americas Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Country (2018-2023)
5.2 Americas Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Type
5.3 Americas Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Region
6.1.1 APAC Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Region (2018-2023)
6.1.2 APAC Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Region (2018-2023)
6.2 APAC Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Type
6.3 APAC Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Bruton Tyrosine Kinase (BTK) Inhibitor by Country
7.1.1 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Country (2018-2023)
7.1.2 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Country (2018-2023)
7.2 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Type
7.3 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitor by Country
8.1.1 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Country (2018-2023)
8.1.2 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Country (2018-2023)
8.2 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Type
8.3 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Bruton Tyrosine Kinase (BTK) Inhibitor
10.3 Manufacturing Process Analysis of Bruton Tyrosine Kinase (BTK) Inhibitor
10.4 Industry Chain Structure of Bruton Tyrosine Kinase (BTK) Inhibitor
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Bruton Tyrosine Kinase (BTK) Inhibitor Distributors
11.3 Bruton Tyrosine Kinase (BTK) Inhibitor Customer
12 World Forecast Review for Bruton Tyrosine Kinase (BTK) Inhibitor by Geographic Region
12.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Market Size Forecast by Region
12.1.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Forecast by Region (2024-2029)
12.1.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Bruton Tyrosine Kinase (BTK) Inhibitor Forecast by Type
12.7 Global Bruton Tyrosine Kinase (BTK) Inhibitor Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolios and Specifications
13.1.3 Pfizer Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Aptose Eiosciences
13.2.1 Aptose Eiosciences Company Information
13.2.2 Aptose Eiosciences Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolios and Specifications
13.2.3 Aptose Eiosciences Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Aptose Eiosciences Main Business Overview
13.2.5 Aptose Eiosciences Latest Developments
13.3 BeiGene
13.3.1 BeiGene Company Information
13.3.2 BeiGene Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolios and Specifications
13.3.3 BeiGene Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 BeiGene Main Business Overview
13.3.5 BeiGene Latest Developments
13.4 Hanmi Phamaceutical
13.4.1 Hanmi Phamaceutical Company Information
13.4.2 Hanmi Phamaceutical Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolios and Specifications
13.4.3 Hanmi Phamaceutical Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Hanmi Phamaceutical Main Business Overview
13.4.5 Hanmi Phamaceutical Latest Developments
13.5 Eli Lilly
13.5.1 Eli Lilly Company Information
13.5.2 Eli Lilly Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolios and Specifications
13.5.3 Eli Lilly Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Eli Lilly Main Business Overview
13.5.5 Eli Lilly Latest Developments
13.6 Merck
13.6.1 Merck Company Information
13.6.2 Merck Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolios and Specifications
13.6.3 Merck Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Merck Main Business Overview
13.6.5 Merck Latest Developments
13.7 Ono Phamaceutical
13.7.1 Ono Phamaceutical Company Information
13.7.2 Ono Phamaceutical Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolios and Specifications
13.7.3 Ono Phamaceutical Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Ono Phamaceutical Main Business Overview
13.7.5 Ono Phamaceutical Latest Developments
13.8 AbbVie
13.8.1 AbbVie Company Information
13.8.2 AbbVie Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolios and Specifications
13.8.3 AbbVie Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 AbbVie Main Business Overview
13.8.5 AbbVie Latest Developments
13.9 Zhejiang DTRM Biopharma
13.9.1 Zhejiang DTRM Biopharma Company Information
13.9.2 Zhejiang DTRM Biopharma Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolios and Specifications
13.9.3 Zhejiang DTRM Biopharma Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Zhejiang DTRM Biopharma Main Business Overview
13.9.5 Zhejiang DTRM Biopharma Latest Developments
13.10 AstraZeneca
13.10.1 AstraZeneca Company Information
13.10.2 AstraZeneca Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolios and Specifications
13.10.3 AstraZeneca Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 AstraZeneca Main Business Overview
13.10.5 AstraZeneca Latest Developments
13.11 Biogen
13.11.1 Biogen Company Information
13.11.2 Biogen Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolios and Specifications
13.11.3 Biogen Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Biogen Main Business Overview
13.11.5 Biogen Latest Developments
14 Research Findings and Conclusion